Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Calvo DM"'
Autor:
Leache,L, Celaya,MC, Alzueta,N, Echeverría,A, Saiz,LC, Erviti,J, Garjón,J, Fontela,C, Sanz,L, Acín,MT, Fernández,ML, Gómez,N, Gutiérrez-Valencia,M, Calvo,DM
Publikováno v:
Revista de la OFIL v.31 n.4 2021
SciELO España. Revistas Científicas Españolas de Ciencias de la Salud
instname
SciELO España. Revistas Científicas Españolas de Ciencias de la Salud
instname
SUMMARY Objective: Acute kidney injury (AKI) is a life-threatening condition characterized by an abrupt deterioration in kidney function. The simultaneous use of diuretics, renin-angiotensin-aldosterone system inhibitors, and non-steroidal anti-infla
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::5eb3582ff086c47107779552d365c8f8
http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1699-714X2021000400015
http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1699-714X2021000400015
Autor:
Calvo DM; Autonomous University of Barcelona (UAB), Barcelona, Spain., Saiz LC; Unit of Innovation and Organization, Navarre Health Service, Navarra Health Research Institute (IdiSNA), Pamplona, Spain., Leache L; Unit of Innovation and Organization, Navarre Health Service, Navarra Health Research Institute (IdiSNA), Pamplona, Spain., Celaya MC; Subdirectorate of Pharmacy and Health Benefits, Navarre Health Service, Navarra Health Research Institute (IdiSNA), Pamplona, Spain., Gutiérrez-Valencia M; Unit of Innovation and Organization, Navarre Health Service, Navarra Health Research Institute (IdiSNA), Pamplona, Spain., Alonso A; Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA., Erviti J; Unit of Innovation and Organization, Navarre Health Service, Navarra Health Research Institute (IdiSNA), Pamplona, Spain., Alzueta N; Subdirectorate of Pharmacy and Health Benefits, Navarre Health Service, Navarra Health Research Institute (IdiSNA), Pamplona, Spain., Echeverría A; Subdirectorate of Pharmacy and Health Benefits, Navarre Health Service, Navarra Health Research Institute (IdiSNA), Pamplona, Spain., Garjón J; Subdirectorate of Pharmacy and Health Benefits, Navarre Health Service, Navarra Health Research Institute (IdiSNA), Pamplona, Spain., Fontela C; Pharmacy Service, Donostia University Hospital, OSI Donostialdea, Osakidetza, San Sebastián, Spain., Sanz L; Subdirectorate of Pharmacy and Health Benefits, Navarre Health Service, Pamplona, Spain., Acín MT; Subdirectorate of Pharmacy and Health Benefits, Navarre Health Service, Navarra Health Research Institute (IdiSNA), Pamplona, Spain., Fernández ML; Nephrology Service, Navarre University Hospital, Navarre Health Service, Navarra Health Research Institute (IdiSNA), Pamplona, Spain., Gómez N; Nephrology Service, Navarre University Hospital, Navarre Health Service, Navarra Health Research Institute (IdiSNA), Pamplona, Spain.
Publikováno v:
Pharmacoepidemiology and drug safety [Pharmacoepidemiol Drug Saf] 2023 Aug; Vol. 32 (8), pp. 898-909. Date of Electronic Publication: 2023 Apr 05.
